The state of Florida currently has 80 active clinical trials seeking participants for Diabetes research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Recruiting
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Suncoast Clinical Research, Inc., New Port Richey, Florida
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
REsearching Covid-19 Outcomes in Diabetes (RECODE)
Recruiting
The purpose of this study is to observe any changes that may occur to certain organs following a confirmed diagnosis of COVID-19 in people with and without diabetes.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: AdventHealth Translational Research Institute, Orlando, Florida
Conditions: Covid19, Diabetes
Combining Shockwave Therapy and Platelet Rich Plasma to Treat Erectile Dysfunction in Diabetic Men (COCKTAIL-DM)
Recruiting
The purpose of this research study is to evaluate whether the combination of Shockwave Therapy (SWT) with Platelet Rich Plasma (PRP) is synergistic and can reverse the pathology of microvascular Erectile Dysfunction (ED) and enhance erectile function in diabetics patients.
Gender:
Male
Ages:
Between 30 years and 80 years
Trial Updated:
06/20/2024
Locations: University of Miami, School of Medicine - Desai Sethi Urology Institute, Miami, Florida
Conditions: Erectile Dysfunction With Diabetes Mellitus
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: Clinical Research of West Florida, Inc. (Clearwater), Clearwater, Florida +6 locations
Conditions: Type 2 Diabetes
Liraglutide Effects on Epicardial Fat Inflammatory Genes
Recruiting
Epicardial adipose tissue (EAT) is the visceral fat of the heart. EAT could locally affect the coronary arteries through local secretion of pro-inflammatory cytokines. EAT plays a role in the development of the coronary artery disease (CAD). EAT is a highly enriched with genes involved in inflammation. Given its rapid metabolism and simple measurability, as first developed by Iacobellis, EAT serves as target for medications targeting the fat. Glucagon-like peptide-1 agonists (GLP-1A) are anti-di... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: University of Miami, Miami, Florida
Conditions: Type2 Diabetes, Coronary Artery Disease
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
All
Ages:
Between 12 years and 28 years
Trial Updated:
06/19/2024
Locations: Diabetes Research Institute (DRI)-University of Miami Leonard M. Miller School of Medicine (UMMSM), Miami, Florida
Conditions: Type 1 Diabetes Mellitus
A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting
Recruiting
This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability to filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a re... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/19/2024
Locations: University of Central Florida College of Medicine, Orlando, Florida +3 locations
Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/19/2024
Locations: Retreat Medical Research, Miami, Florida +1 locations
Conditions: Type 2 Diabetes, Obesity
A Safety, Tolerability, and Efficacy Study of VX-264 in Participants With Type 1 Diabetes
Recruiting
The purpose of the study is to evaluate the safety, tolerability, and efficacy of VX-264 in participants with type 1 diabetes (T1D).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/17/2024
Locations: UHealth Diabetes Research Institute, Miami, Florida
Conditions: Type 1 Diabetes
A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study will last approximately 2 years may include up to 27 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Orlando Heart & Vascular Institute, Altamonte Springs, Florida +23 locations
Conditions: Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight
Recruiting
The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Excel Medical Clinical Trials, Boca Raton, Florida +8 locations
Conditions: Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
Recruiting
The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: Arrow Clinical Trials, Daytona Beach, Florida +3 locations
Conditions: Diabetes Mellitus, Type 2